NCT04004442 2026-03-13
COAXIN
University of Oklahoma
Phase 1 Active not recruiting
Clinical Trials
16 trialsNCT03719768 2026-03-02
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03252938 2026-02-19
INSIGHT
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1 Active not recruiting
NCT04360941 2026-01-21
PAveMenT
Royal Marsden NHS Foundation Trust
Phase 1 Recruiting
NCT03575013 2025-12-03
A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer
University of Iowa
Phase 1 Completed
NCT04387084 2025-09-05
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT04242238 2025-08-28
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03498378 2025-04-03
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of California, San Diego
Phase 1 Active not recruiting
NCT03893903 2025-03-14
AMPLIFY-NEOVAC
German Cancer Research Center
Phase 1 Completed
NCT03636503 2025-02-06
Rituximab + Immunotherapy in Follicular Lymphoma
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT03200587 2024-07-03
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
University of Utah
Phase 1 Completed
NCT03267836 2023-06-15
Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
Washington University School of Medicine
Phase 1 Terminated
NCT03502681 2022-07-01
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Big Ten Cancer Research Consortium
Phase 1 Terminated
NCT03514719 2022-01-10
PINNACLE
Radboud University Medical Center
Phase 1 Completed
NCT03341806 2022-01-04
Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT02938273 2019-12-11
Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)
The Netherlands Cancer Institute
Phase 1 Completed